{"id":"W3135098376","doi":"10.1016/j.annonc.2021.02.017","title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":292,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Medicine; Topotecan; Internal medicine; Clinical endpoint; Ovarian cancer; Tolerability; Oncology; Population; Hazard ratio; Chemotherapy; Chemotherapy regimen; Progression-free survival; Cancer; Randomized controlled trial; Surgery; Adverse effect; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002681448,0.001777088,0.003323338,0.0004244124,0.0003746591,0.001077631,0.0009369766,0.001547102,0.006591579],"category_scores_gemma":[0.002131047,0.0008237114,0.002951165,0.0004284614,0.001020475,0.0008980476,0.0004045166,0.002780505,0.0009964078],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001219991,"about_ca_system_score_gemma":0.001894553,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001253383,"about_ca_topic_score_gemma":0.003503246,"domain_scores_codex":[0.9991304,0.0005235272,0.00003214747,0.0001391706,0.00004547523,0.0001292935],"domain_scores_gemma":[0.9984694,0.0004306473,0.000357782,0.0001498312,0.00009910535,0.0004931131],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.977757,0.00726256,0.000771595,0.0003122627,0.0007010227,0.0000342867,0.00003786046,0.0004920638,0.00240558,0.00008264265,0.0007866923,0.009356428],"study_design_scores_gemma":[0.884249,0.1113374,0.002038678,0.00002502912,0.0005387681,0.00003606307,0.00002037643,0.0004815463,0.0005322653,0.000157414,0.0005689307,0.00001456792],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9813049,0.003765272,0.0008382873,0.0008913975,0.0005830827,0.007388701,0.002292695,0.000119837,0.002815821],"genre_scores_gemma":[0.9811088,0.002070182,0.002007224,0.00119387,0.0005246308,0.00603766,0.002216378,0.00004420348,0.004796982],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006591579,"threshold_uncertainty_score":0.02205104,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03864959317361016,"score_gpt":0.3720440515617144,"score_spread":0.3333944583881043,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}